COX-2 Advisory Committee Review Will Include New Celebrex Safety Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee will also “explore ways of further evaluation” of the safety of Pfizer’s Bextra and COX-2s approved in Europe, such as Merck’s Arcoxia. FDA also expects discussion of broader NSAID category, at least for “context.”